Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, phase II clinical trial.
Authors: Yanhong Gu, Tianzhu Qiu, Lu Mingjie, Yuwen Dong
Published: 2025-01-27
DOI:
10.1200/jco.2025.43.4_suppl.445
Source:
Full article
Abstract
445